Decreased Serum Monocyte Chemoattractant Protein-1 in Salivary Gland Tumor Patients

  • Mardani, Maryam (Department of Oral Medicine, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Andisheh-Tadbir, Azadeh (Prevention of Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences) ;
  • Khademi, Bijan (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Melekzadeh, Mahyar (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Vaziri, Lida (Undergraduate Student, School of Dentistry Shiraz University of Medical Sciences)
  • Published : 2016.07.01


Background: The monocyte chemoattractant protein-1 (MCP-1/CCL2) is a potent chemoattractant for natural killer cells, monocytes, and memory T lymphocytes. However, any role in the genesis of salivary gland tumors (SGT) is unknown. To assess the diagnostic relevance of chemokines in SGT, MCP-1 levels in the serum of patients were investigated in association with tumor progression and clinical aggressiveness. Materials and Methods: Using an ELISA kit, we assessed and compared the circulating levels of MCP-1 in blood serum of 70 SGT patients with 44 healthy control samples. Results: The results of this study showed that the concentration of MCP-1 was significantly lower in patients with benign ($463.8{\pm}158.5pg/ml$, P=0.033) and malignant ($454.8{\pm}190.4pg/ml$, P=0.007) SGT than in healthy subjects ($645.7{\pm}338.9$). No significant difference in mean serum levels of MCP-1 was observed between the benign and malignant group (p=0.9). While MCP-1 levels were lower in patients with an advanced clinical stage, advanced tumor size, higher tumor grade, or lymph node involvement, but the mean MCP-1 level between groups showed no statistically significant difference (p>0.05). Conclusions: MCP-1 levels in the serum of patients with SGT were decreased, indicating that this might a good marker for discriminating patients with SGT from healthy people. However, no clear-cut relationship was detected between MCP-1 levels and clinicopathologic factors, and MCP-1 is not a good marker for evaluating tumor dissemination.


Supported by : Shiraz University of Medical Sciences


  1. Andisheh-Tadbir A, Khademi B, Malekzadeh M, et al (1014). Monocyte chemoattractant protein-1 serum levels in patients with oral squamous cell carcinoma. J Biol Sci, 14, 322.
  2. Bolat F, Kayaselcuk F, Nursal TZ, et al (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res, 25, 365-72.
  3. Church TS, Willis MS, Priest EL, et al (2005). Obesity, macrophage migration inhibitory factor, and weight loss. Int J Obes, 29, 675-81.
  4. Christiansen T, Richelsen B, Bruun JM (2005). Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes, 29, 146-50.
  5. Deshmane SL, Kremlev S, Amini S, et al(2009). Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res, 29, 313-26.
  6. Ding L, Li B, Zhao Y, et al (2014). Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma. Tumour Biol, 3, 10539-46.
  7. Heywood G, Vezeridis MP, Wanebo HJ(1998). Surgical therapy of pancreatic cancer. Front biosci, 3, 175-80.
  8. Huang S, Singh RK, Xie K, et al(1994). Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother, 39, 231-8.
  9. Ishioka K, Suzuki Y, Tajima K, et al (2013). Monocyte chemoattractant protein-1 in dogs affected with neoplasia or inflammation. J Vet Med Sci, 75, 173-7.
  10. Jaafari-Ashkavandi Z, Ashraf MJ, Moshaverinia M (2013). Salivary gland tumors: a clinicopathologic study of 366 cases in southern Iran. Asian Pac J Cancer Prev, 14, 27-30.
  11. Kantola T, Klintrup K, Vayrynen JP, et al (2012). Stagedependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer, 107, 1729-36.
  12. Klintrup K, Makinen JM, Kauppila S, et al (2005). Inflammation and prognosis in colorectal cancer. Eur J Can, 41, 2645-54.
  13. Koizumi K, Hojo S, Akashi T, et al(2007). Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci, 98, 1652-8.
  14. Loberg RD, Ying C, Craig M, et al (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9, 556-62.
  15. Matsushima K, Larsen CG, DuBois GC, et al (1989). Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med, 169, 1485-90.
  16. Monti P, Leone BE, Marchesi F, et al (2003). The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res, 63, 7451-61.
  17. Nakashima E, Mukaida N, Kubota Y,et al (1995). Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res, 12, 1598-604.
  18. Nakashima J, Tachibana M, Ueno M, et al(1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res, 4, 1743-8.
  19. Negus RP, Stamp GW, Relf MG, et al (1995). The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest, 95, 2391-6.
  20. Nesbit M, Schaider H, Miller TH, et al (2001). Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol, 166, 6483-90.
  21. Ohta M, Kitadai Y, Tanaka S, et al(2003). Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol, 22, 773-8.
  22. Razmkhah M, Arabpour F, Taghipour M,et al (2014). Expression of chemokines and chemokine receptors in brain tumor tissue derived cells. Asian Pac J Cancer Prev, 15, 201-5.
  23. Sambyal V, Guleria K, Kapahi R,et al (2015). Association of the -2518 A/G polymorphism of MCP-1 with breast cancer in Punjab, North-West India. Asian Pac J Cancer Prev, 16, 7243-8.
  24. Tonouchi H, Miki C, Tanaka K, et al (2002). Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Scand J Gastroenterolm, 7, 830-3.
  25. Tsaur I, Noack A, Waaga-Gasser AM, et al (2001). Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomark, 10, 195-204.
  26. Ueno T, Toi M, Saji H, et al(2000). Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res, 6, 3282-9.
  27. Valkovic T, Lucin K, Krstulja M, et al (1998). Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract, 194, 335-40.
  28. Wang WW, Ang SF, Kumar R, et al (2013). Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PloS One, 8, 68904.
  29. Waugh DJ, Wilson C, Seaton A, et al (2008). Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci, 13, 4595-604.
  30. Wu J, Liu X, Wang Y (2013). Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer. BMC Clinical Pathol, 13, 15.
  31. Yoshimura T, Robinson EA, Tanaka S, et al (1989). Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med, 169, 1449-59.